Education
About Us
Working with TipRanks
Follow Us
Alto Neuroscience, Inc. (ANRO)
NYSE:ANRO
ANRO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.53 - $18.31
Previous CloseN/A
Volume104.17K
Average Volume (3M)377.58K
Market Cap
$68.49M
Enterprise Value-$37.13M
Total Cash (Recent Filing)$48.34M
Total Debt (Recent Filing)$82.11M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
May 20, 2025EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.28
Shares Outstanding27,072,128
10 Day Avg. Volume258,187
30 Day Avg. Volume377,581
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)10.79
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit99.55
Enterprise Value/Ebitda0.67
Forecast
1Y Price Target
$12.25Price Target Upside384.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Alto Neuroscience, Inc. News
PremiumStock Analysis & Ideas
Jefferies Predicts Up to ~500% Jump for These 2 ‘Strong Buy’ StocksPremiumCompany Announcements
Alto Neuroscience Advances Clinical Trials with Strong FinancialsPremiumCompany Announcements
Alto Neuroscience Announces Board Member Departures---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase IIb trial of ALTO-300 will continue with an increase of approximately 50 patients positive for the ALTO-300 biomarker, indicating promising interim results.
Financial ProjectionsALTO-300 is estimated to potentially generate risk-adjusted net revenue of approximately $1 billion in the U.S. for Major Depressive Disorder by the fiscal year 2036.
Financial StabilityANRO's cash runway is expected to last into 2028, providing long-term financial stability for ongoing and future projects.
Bears Say
Financial PerformanceThe net loss reported for 4Q24 was $15.2M, which may concern some investors despite the potential positive outcomes of ongoing trials.
Regulatory DelaysThe expected approval of ALTO-300 has been pushed back to the third quarter of 2030 due to the increase in target enrollment for the Phase IIb trial.
Timeline DelaysThe company faced a delay in the data readout for the ALTO-300 study due to additional patient enrollment, pushing the timeline to mid-2026.
---
Ownership Overview
14.69% Insiders
10.50% Mutual Funds
33.31% Other Institutional Investors
33.61% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ANRO FAQ
What was Alto Neuroscience, Inc.’s price range in the past 12 months?
Alto Neuroscience, Inc. lowest stock price was $2.53 and its highest was $18.31 in the past 12 months.
What is Alto Neuroscience, Inc.’s market cap?
Alto Neuroscience, Inc.’s market cap is $68.49M.
When is Alto Neuroscience, Inc.’s upcoming earnings report date?
Alto Neuroscience, Inc.’s upcoming earnings report date is May 20, 2025 which is in 54 days.
How were Alto Neuroscience, Inc.’s earnings last quarter?
Alto Neuroscience, Inc. released its earnings results on Mar 20, 2025. The company reported -$0.52 earnings per share for the quarter, beating the consensus estimate of -$0.646 by $0.126.
Is Alto Neuroscience, Inc. overvalued?
According to Wall Street analysts Alto Neuroscience, Inc.’s price is currently Undervalued.
Does Alto Neuroscience, Inc. pay dividends?
Alto Neuroscience, Inc. does not currently pay dividends.
What is Alto Neuroscience, Inc.’s EPS estimate?
Alto Neuroscience, Inc.’s EPS estimate is -0.64.
How many shares outstanding does Alto Neuroscience, Inc. have?
Alto Neuroscience, Inc. has 27,072,128 shares outstanding.
What happened to Alto Neuroscience, Inc.’s price movement after its last earnings report?
Alto Neuroscience, Inc. reported an EPS of -$0.52 in its last earnings report, beating expectations of -$0.646. Following the earnings report the stock price went down -3.929%.
Which hedge fund is a major shareholder of Alto Neuroscience, Inc.?
Currently, no hedge funds are holding shares in ANRO
---
Alto Neuroscience, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.25 (384.19% Upside)
$12.25 (384.19% Upside)
Hedge Fund Trend
Decreased
By 1.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 280.5%
Last 30 Days ▲ 280.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.80%
12-Months-Change
Fundamentals
Return on Equity
-153.99%
Trailing 12-Months
Asset Growth
104.95%
Trailing 12-Months
Company Description
Alto Neuroscience, Inc.
Alto Neuroscience, Inc. (ANRO) is a biotechnology company focused on developing precision medicine approaches for the treatment of mental health disorders. The company leverages advancements in brain biomarkers and artificial intelligence to create personalized treatment plans for conditions such as depression and anxiety. By integrating cutting-edge neuroscience with clinical data, Alto aims to provide effective and targeted therapeutic solutions.
---
ANRO Stock 12 Month Forecast
Average Price Target
$12.25
▲(384.19% Upside)
Technical Analysis
Cytokinetics
―
Minerva Neurosciences
―
SAGE Therapeutics
―
Axsome Therapeutics
―
Mind Medicine
―
Best Analysts Covering ANRO
1 Year
1 Year Success Rate
0/10 ratings generated profit
1 Year Average Return
-56.87%
reiterated a buy rating 7 days ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -56.87% per trade.
---